SK112999A3 - Phytosterol composition for preventing alzheimer's disease - Google Patents
Phytosterol composition for preventing alzheimer's disease Download PDFInfo
- Publication number
- SK112999A3 SK112999A3 SK1129-99A SK112999A SK112999A3 SK 112999 A3 SK112999 A3 SK 112999A3 SK 112999 A SK112999 A SK 112999A SK 112999 A3 SK112999 A3 SK 112999A3
- Authority
- SK
- Slovakia
- Prior art keywords
- disease
- apo
- alzheimer
- beta
- sitosterol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/993,901 US5985936A (en) | 1997-12-18 | 1997-12-18 | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
PCT/CA1998/001147 WO1999032097A2 (en) | 1997-12-18 | 1998-12-18 | Phytosterol composition for preventing alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
SK112999A3 true SK112999A3 (en) | 2001-11-06 |
Family
ID=25540052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1129-99A SK112999A3 (en) | 1997-12-18 | 1998-12-18 | Phytosterol composition for preventing alzheimer's disease |
Country Status (18)
Country | Link |
---|---|
US (1) | US5985936A (no) |
EP (1) | EP0967982A2 (no) |
CN (1) | CN1252724A (no) |
AU (1) | AU1656099A (no) |
BG (1) | BG103740A (no) |
BR (1) | BR9807577A (no) |
CA (1) | CA2281710A1 (no) |
EE (1) | EE9900354A (no) |
GE (1) | GEP20022783B (no) |
HU (1) | HUP0100737A3 (no) |
LT (1) | LT4801B (no) |
LV (1) | LV12438B (no) |
MD (1) | MD1920F2 (no) |
NO (1) | NO993979L (no) |
PL (1) | PL335421A1 (no) |
RU (1) | RU2173151C2 (no) |
SK (1) | SK112999A3 (no) |
WO (1) | WO1999032097A2 (no) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060141036A1 (en) * | 1997-12-12 | 2006-06-29 | Andrx Labs Llc | HMG-CoA reductase inhibitor extended release formulation |
US20020107173A1 (en) * | 1999-11-04 | 2002-08-08 | Lawrence Friedhoff | Method of treating amyloid beta precursor disorders |
AU780624B2 (en) * | 1999-11-04 | 2005-04-07 | Andrx Corporation | Method of treating amyloid beta precursor disorders |
CN1436047A (zh) | 2000-04-14 | 2003-08-13 | 马尔斯公司 | 促进血管健康的组合物和方法 |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
US20030013692A1 (en) * | 2001-01-19 | 2003-01-16 | Gullans Steven R. | Methods of treating neurological disorders |
WO2002064735A2 (en) * | 2001-02-12 | 2002-08-22 | Akzo Nobel N.V. | Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 |
US6399310B1 (en) | 2001-02-12 | 2002-06-04 | Akzo Nobel N.V. | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
US20030105082A1 (en) * | 2001-12-03 | 2003-06-05 | Murphy Greer Marechal | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
DE10154221A1 (de) * | 2001-11-07 | 2003-05-15 | Max Delbrueck Centrum | Mittel zur Behandlung von Läsionen des Nervensystems |
FR2848452B1 (fr) * | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
WO2004081002A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
US7208486B2 (en) | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
JP2006519869A (ja) * | 2003-03-07 | 2006-08-31 | シェーリング コーポレイション | 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用 |
US20080182801A1 (en) | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
GB0329667D0 (en) * | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
GB0513881D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
JP2007526764A (ja) * | 2004-01-22 | 2007-09-20 | ジェネッサンス ファーマシューティカルズ,インコーポレイティド | アルツハイマー病の発症年齢に関連するapoe遺伝子マーカー |
EP1814575A4 (en) * | 2004-11-24 | 2010-07-07 | Neopro Labs Llc | METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
GB0512726D0 (en) * | 2005-06-22 | 2005-07-27 | Btg Int Ltd | Multiple sclerosis therapy and diagnosis |
GB0513883D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Diagnosis of Atherosclerosis |
GB0513888D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
MX2010009649A (es) * | 2008-03-27 | 2010-12-17 | Evotecv Neurosciences Gmbh | Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda. |
WO2010104375A1 (en) * | 2009-03-12 | 2010-09-16 | N.V. Nutricia | Stigmasterol for the treatment of alzheimer's disease |
US10383886B2 (en) | 2010-01-11 | 2019-08-20 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with oleandrin |
US9011937B2 (en) | 2010-11-22 | 2015-04-21 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
US10307450B2 (en) | 2010-01-11 | 2019-06-04 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
WO2012149111A1 (en) | 2011-04-26 | 2012-11-01 | The Regents Of The University Of California | Methods of promoting cns neuronal repair by inhibiting lrp-1 |
CN102813659A (zh) * | 2012-08-21 | 2012-12-12 | 贵阳中医学院 | 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途 |
WO2015123617A1 (en) * | 2014-02-14 | 2015-08-20 | Arizona Board Of Regents For The University Of Arizona | Method for reducing bcl2 gene expression |
US10702567B2 (en) | 2016-09-14 | 2020-07-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infection |
US10596186B2 (en) | 2016-09-14 | 2020-03-24 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infections |
RU2758376C2 (ru) | 2017-09-14 | 2021-10-28 | Феникс Байотекнолоджи, Инк. | Способ и улучшенная нейропротекторная композиция для лечения неврологических патологических состояний |
US11331291B2 (en) | 2017-09-14 | 2022-05-17 | Phoenix Biotechnology, Inc. | Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders |
EP3842039A1 (en) * | 2019-12-24 | 2021-06-30 | Folium Biosciences Europe B.V. | Food supplement comprising cannbinoids and phytosterols for alzheimer |
US20230263809A1 (en) | 2019-12-24 | 2023-08-24 | Folium Biosciences Europe B.V. | Food supplement for alzheimer |
US11806359B2 (en) | 2020-03-31 | 2023-11-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating Coronavirus infection |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1203515B (it) * | 1987-02-26 | 1989-02-15 | Indena Spa | Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono |
WO1994018994A1 (en) * | 1993-02-23 | 1994-09-01 | Pharmakon Usa, Inc. | Therapeutic herbal composition |
US5589182A (en) * | 1993-12-06 | 1996-12-31 | Tashiro; Renki | Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression |
BR9509119A (pt) * | 1994-09-29 | 1997-10-28 | Univ British Columbia | Processo para o isolamento de uma composição de fitoesteróis a partir de um sabão de polpa composição diminuidora de colesterol e produto terapeuticamente eficaz para prevenir ou tratar aterosclerose ou dislipidemias primárias ou secundárias |
CN1179903A (zh) * | 1996-10-09 | 1998-04-29 | 李辉 | 营养丝米粉 |
ES2285772T3 (es) * | 1997-05-15 | 2007-11-16 | University Of Washington | Composicion y metodos para tratar la enfermedad de alzheimer y otras amiloidosis. |
-
1997
- 1997-12-18 US US08/993,901 patent/US5985936A/en not_active Expired - Fee Related
-
1998
- 1998-12-18 MD MD99-0262A patent/MD1920F2/ro unknown
- 1998-12-18 WO PCT/CA1998/001147 patent/WO1999032097A2/en not_active Application Discontinuation
- 1998-12-18 AU AU16560/99A patent/AU1656099A/en not_active Abandoned
- 1998-12-18 PL PL98335421A patent/PL335421A1/xx unknown
- 1998-12-18 CA CA002281710A patent/CA2281710A1/en not_active Abandoned
- 1998-12-18 EP EP98960959A patent/EP0967982A2/en not_active Ceased
- 1998-12-18 HU HU0100737A patent/HUP0100737A3/hu unknown
- 1998-12-18 GE GEAP19984990A patent/GEP20022783B/en unknown
- 1998-12-18 RU RU99120072/14A patent/RU2173151C2/ru not_active IP Right Cessation
- 1998-12-18 SK SK1129-99A patent/SK112999A3/sk unknown
- 1998-12-18 BR BR9807577-2A patent/BR9807577A/pt not_active IP Right Cessation
- 1998-12-18 CN CN98804259A patent/CN1252724A/zh active Pending
- 1998-12-18 EE EEP199900354A patent/EE9900354A/xx unknown
-
1999
- 1999-08-18 NO NO993979A patent/NO993979L/no not_active Application Discontinuation
- 1999-09-16 LT LT1999114A patent/LT4801B/lt not_active IP Right Cessation
- 1999-09-17 LV LVP-99-134A patent/LV12438B/en unknown
- 1999-09-17 BG BG103740A patent/BG103740A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
PL335421A1 (en) | 2000-04-25 |
MD1920F2 (ro) | 2002-05-31 |
GEP20022783B (en) | 2002-09-25 |
CA2281710A1 (en) | 1999-07-01 |
LV12438A (en) | 2000-03-20 |
US5985936A (en) | 1999-11-16 |
WO1999032097A2 (en) | 1999-07-01 |
LV12438B (en) | 2000-09-20 |
RU2173151C2 (ru) | 2001-09-10 |
EP0967982A2 (en) | 2000-01-05 |
HUP0100737A3 (en) | 2002-07-29 |
BG103740A (en) | 2000-05-31 |
WO1999032097A3 (en) | 1999-09-02 |
AU1656099A (en) | 1999-07-12 |
MD990262A (en) | 2000-06-30 |
NO993979L (no) | 1999-10-13 |
BR9807577A (pt) | 2001-08-07 |
EE9900354A (et) | 2000-02-15 |
CN1252724A (zh) | 2000-05-10 |
NO993979D0 (no) | 1999-08-18 |
LT4801B (lt) | 2001-06-25 |
HUP0100737A2 (hu) | 2001-09-28 |
LT99114A (lt) | 2001-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2173151C2 (ru) | Способ и композиция для профилактики и задержки начала болезни альцгеймера | |
Troutwine et al. | Apolipoprotein E and Alzheimer's disease | |
Salem Jr et al. | The benefit of docosahexaenoic acid for the adult brain in aging and dementia | |
Leduc et al. | APOE and cholesterol homeostasis in Alzheimer's disease | |
Anil | The impact of EPA and DHA on blood lipids and lipoprotein metabolism: influence of apoE genotype | |
Hottman et al. | HDL and cognition in neurodegenerative disorders | |
Martin et al. | Brain cholesterol in normal and pathological aging | |
Wang et al. | Lipoprotein lipase in the brain and nervous system | |
Chernick et al. | Peripheral versus central nervous system APOE in Alzheimer’s disease: Interplay across the blood-brain barrier | |
Maria Giudetti et al. | The role of brain cholesterol and its oxidized products in Alzheimer's disease | |
JP2004505910A (ja) | アポリポタンパク質e分泌を誘導するための方法 | |
Xiao et al. | DHA ameliorates cognitive ability, reduces amyloid deposition, and nerve fiber production in Alzheimer’s disease | |
Turri et al. | Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders | |
Uddin et al. | Emerging therapeutic promise of ketogenic diet to attenuate neuropathological alterations in Alzheimer’s disease | |
Takechi et al. | Chylomicron amyloid-beta in the aetiology of Alzheimer's disease | |
Lovati et al. | Increased plasma and aortic triglycerides in rabbits after acute administration of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin | |
Liu et al. | Insulin Resistance and impaired branched-chain amino acid metabolism in Alzheimer’s Disease | |
Zhou et al. | Prenatal ethanol exposure up-regulates the cholesterol transporters ATP-binding cassette A1 and G1 and reduces cholesterol levels in the developing rat brain | |
Mas et al. | Functional Vitamin E deficiency in ApoE4 patients with Alzheimer’s disease | |
Paseban et al. | The role of the ATP-binding cassette A1 (ABCA1) in neurological disorders: a mechanistic review | |
Pamir et al. | Overexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis | |
CZ9902921A3 (cs) | Léčivo pro profylaxi nebo zpomalení rozvoje Alzheimerovy choroby a terapeuticky účinný produkt k prevenci Alzheimerovy choroby | |
Plourde | Aging, cognitive decline, apolipoprotein E and docosahexaenoic acid metabolism | |
MXPA99007622A (en) | Method of preventing and delaying the onset of alzheimer's disease and composition therefor | |
JP2001512494A (ja) | アルツハイマー病を予防するまたはその発病を遅延させる方法およびそのための組成物 |